

**IN THE SPECIFICATION**

Please amend the paragraph beginning on page 3, Line 18, as follows

It is not intended that the present invention be limited to particular ACE inhibitor. Indeed, a variety of ACE inhibitors are contemplated. In one embodiment, the ACE inhibitor is enalaprilat. In other embodiments, the ACE inhibitor is selected from the group consisting of alacepril, benazepril (~~LOTENSIN~~Lotensin), captopril (~~CAPOTEN~~Capoten), cilazapril, ceranapril, delapril, enalapril (~~VASOTEC~~Vasotect), fosinopril (~~MONOPRIL~~Monopril), fosinoprilat, imidapril, lisinopril (~~PRINIVIL~~, ~~ZESTRIL~~Prinivil, Zestril), moexipril (~~UNIVASC~~Univase), perindopril (~~ACEON~~Aceon), perindoprilat, quinapril (~~ACCUPRIL~~Accupril), quinaprilat, ramipril (~~ALTACE~~Altace), saralasin acetate, spirapril, temocapril,trandolapril (~~MAVIK~~Mavik), Bioproject BP1.137 (fasidotrilat (benzyl (2S)-2-[[[(2S)-2-(acetylsulfanylmethyl)-3-benzo[1,3]dioxol-5-yl-propanoyl]amino]propanoate )), Chiesi CHF 1514 (beclometasone dipropionate ([2-[(8R,9S,10S,11R,13S,14R,16R,17R)-9-chloro-11-hydroxy-10,13,16-trimethyl-3-oxo-17-propanoyloxy-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxo-ethyl] propanoate))) whos chemical structure is , Fisons FPL-66564 (((2R)-3-methylsulfanyl-2-[(2S)-2-methyl-3-sulfanyl-propanoyl]oxy-propanoic acid)), idrapril, Marion Merrell Dow MDL-100240 (((Pyrido(2,1-a)(2)benzazepine-4-carboxylic acid, 7-((2-(acetylthio)-1-oxo-3-phenylpropyl)amino)-1,2,3,4,6,7,8,12b-octahydro-6-oxo-, (4S-(4 $\alpha$ ,7 $\alpha$ (R\*),12 $\beta$ beta)))-), and Servier S-5590 (a combination of the angiotensin-converting enzyme inhibitor perindopril and the diuretic indapamide).